Delivery Order SPE2DR25D1100-SPE2DR26FCV3E
- Not listed
- The Defense Logistics Agency awarded a $21,827.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of TIBSOVO 250 mg on August 7, 2025, with completion scheduled for August 28, 2025. This non-set-aside award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery order will be fulfilled from AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a $21.8K delivery order to AmerisourceBergen Drug Corp on November 6, 2025, for the supply of Tibsovo (ivosidenib) 250 mg tablets in a quantity of 60 units. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The contract is set to be completed by December 1, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for 60 tablets of TIBSOVO 250 mg, a pharmaceutical product used in oncology treatment. This firm fixed-price delivery order, valued at $21,827.40, was competitively awarded without set-aside provisions and is scheduled for completion by May 14, 2025. The order was placed on April 23, 2025, and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) on November 4, 2025, for TIBSOVO 250 mg tablets (60-count supply) with a firm fixed price ceiling value of $21,827.41. The contract is scheduled for completion by November 26, 2025. This is a competitively awarded, non-set-aside delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $21,827.40, is for the supply of TIBSOVO 250 MG TABLET 60S, a specialty pharmaceutical product. The contract has a period of performance through March 14, 2025, and is a firm fixed-price type. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a delivery order federal contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of TIBSOVO 250 MG TABLET 60S, a pharmaceutical product. The contract has a firm fixed-price pricing type and a ceiling value of $21,827.40. The place of performance is Conshohocken, PA. The contract has an ultimate completion date of July 8, 2025 and was awarded on June 13,...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $97,410.80 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical (DLA) to supply 60 packages of 250 mg TIBSOVO tablets. Performance will take place in Conshohocken, Pennsylvania under a schedule contract held by Amerisourcebergen, with delivery required by September 7, 2023. DLA manages the medical supply chain for the Department of Defense, procuring...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TIBSOVO 250 MG TABLET 60S, a prescription medication, with a total ceiling value of $21,827.40 and a period of performance through July 22, 2025. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen...
- The Defense Logistics Agency awarded a $19,482 firm fixed price delivery order to Amerisourcebergen Drug Corporation for 60 tablets of the oncology drug TIBSOVO (ivosidenib) 250 mg. To be performed in Conshohocken, Pennsylvania under contract number 4562216553, the order has a period of performance from September 18 to October 10, 2023. No set aside designation or subcontractors were identified. The Defense Logistics Agency supports America's armed forces by providing supplies, transportation...
- Amerisourcebergen Drug Corporation, a division of Amerisourcebergen Corporation, has been awarded a $19,482.16 firm fixed price delivery order by the Defense Logistics Agency Troop Support Medical (DLA) to supply 60 tablets of the oncology pharmaceutical TIBSOVO (gilteritinib fumarate) 250mg to a location in Conshohocken, Pennsylvania. Performance will take place between August 4 and August 25, 2023. As the prime contractor, Amerisourcebergen will fulfill the order from its corporate...
- SPE2DR25D1100Indefinite Delivery Contract
- SPE2DR25D1100-SPE2DR26FCV3EDelivery Order
The Defense Logistics Agency awarded a $23,002.73 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of TIBSOVO 250 mg, with a completion date of January 9, 2026. This non-set-aside contract was competitively awarded and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania. TIBSOVO (ivosidenib) is a targeted cancer therapy used primarily for acute myeloid leukemia treatment. As a major pharmaceutical distributor and critical vendor for federal medical procurement, AmerisourceBergen supplies a comprehensive range of medications and medical supplies to support military and veteran healthcare systems. This delivery order fulfills DLA's medical supply chain requirements through the company's prime vendor agreement, enabling efficient procurement of specialty pharmaceuticals across multiple therapeutic domains to support Defense Health Agency operations and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.0k | 12/16/25 |